Validity of the UK early access to medicines scheme criteria for Remdesivir use in patients with COVID-19 disease
Anna Daunt(Imperial College London), Shevanthi Nayagam(Imperial College London), Pablo N. Perez‐Guzman(Imperial College London), Mark Thursz(Imperial College Healthcare NHS Trust), Céire Costelloe(Imperial College London), Felicity Liew(Imperial College London), Graham Cooke(St Mary's Hospital), Katharina Hauck(Imperial College London)
Cited by 1
Related Papers
The Global Burden of Cancer 2013
|JAMA Oncology|2015|2.8k
Global distribution and prevalence of hepatitis C virus genotypes
|Hepatology|2014|1.6k
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
|The Lancet. Gastroenterology & hepatology|2019|539
Association between an MHC Class II Allele and Clearance of Hepatitis B Virus in the Gambia
|New England Journal of Medicine|1995|439